Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma 1

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1resiquimod 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1gallium maltolate 1fludarabine 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cc-486 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Vorinostat 1Trastuzumab 1Thalidomide 1Sunitinib 1Specimen Handling 1Social Determinants of Health 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × gallium maltolate × Plasma cell × Clear all
NCT00050687 2011-01-28

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Titan Pharmaceuticals

Phase 1/2 Terminated
GenitourinaryLymphoidPlasma cell

Urinary Bladder Neoplasms, Lymphoma, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡